Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brigatinib

FDA-approved product (tablet, oral), marketed as Alunbrig.

Registered studies
48
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brigatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

48registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brigatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brigatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

    NCT02094573 · start 2014-06-04

    Registered record
    Registry ID
    NCT02094573
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-06-04
    Completion
    2020-02-27
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionBrigatinib
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

    NCT01449461 · start 2011-09-20

    Registered record
    Registry ID
    NCT01449461
    Conditions
    Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-09-20
    Completion
    2020-02-18
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung
    InterventionBrigatinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

    NCT02784158

    Registered record
    Registry ID
    NCT02784158
    Conditions
    Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
    Interventions
    Brigatinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
    InterventionBrigatinib
    PhaseNot recorded
    Registry statusNo longer available